Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression
| Autor: | Jay B. Saoud, Philip D. Harvey, Yuliya Blazhevych, Remy Luthringer, Michael H. Davidson, Svetlana Moroz, Cristinel Stefanescu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Indoles Adolescent Anhedonia Apathy Placebo Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Outcome Assessment Health Care Post-hoc analysis Humans Medicine Emotional expression Affective Symptoms Prospective cohort study Biological Psychiatry Avolition Neurotransmitter Agents business.industry Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Tolerability Schizophrenia Female medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Schizophrenia Research. 215:352-356 |
| ISSN: | 0920-9964 |
| Popis: | Background Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound with high affinities for 5 HT2A and sigma2 receptors, has previously shown superiority over placebo on improving NS in a prospective study in patients with schizophrenia. The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. Methods This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores ≥20 on the NS subscale of the PANSS. Patients were randomized to daily monotherapy with roluperidone 32 mg, roluperidone 64 mg, or placebo in a 1:1:1 ratio. All enrolled patients were Caucasian, and 137 (56%) were male. The 3 treatment groups were balanced on all demographic and illness-related baseline characteristics. Results Both doses of roluperidone were superior to placebo on both domains: Reduced Experience (p ≤ .006 for the 32 mg; p ≤ .001 for the 64 mg) with persistent superiority from Week 2 for the 64 mg dose and Week 8 for the 32 mg dose; Reduced Expression (p ≤ .003 for 32 mg; p ≤ .001 for 64 mg) with similar persistence. Implications Both doses of roluperidone previously improved PANSS negative symptoms in general and demonstrated tolerability in stable schizophrenia patients. The post hoc analysis reported here found the drug to work on both the reduced emotional experience and reduced emotional expression sub-scales empirically derived from the PANSS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect